admin - SciBase

2022-05-18 14:15

Today, the annual general meeting of 2022 was held in SciBase Holding AB (publ) (the “Company” or “SciBase”). Below follows a summary of the resolutions passed at the annual general meeting.

The annual general meeting resolved:

to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2021;
that SEK 202,229,730 shall be carried forward in new account and that no dividend shall be paid;
to grant the board members and the CEO discharge from liability for the financial year 2021;
that the board of directors shall consist of five ordinary members without deputy members and that a registered accounting firm shall be elected as auditor;
that the fees payable to the board of directors for the period until the end of the next annual general meeting shall be SEK 200,000 for the chairman of the board and SEK 150,000 to each of the other ordinary board members (who are not employed by a larger shareholder in the Company) and that fees payable to the auditor is to be paid in accordance with approved invoices;
for the period until the end of the next annual general meeting, to re-elect Jvalini Dwarkasing, Diana Ferro, Matt Leavitt, Thomas Taapken and Tord Lendau as board members, to re-elect Tord Lendau as chairman of the board of directors and to re-elect the auditing firm PricewaterhouseCoopers AB (PwC) as auditor for the Company, with Magnus Lagerberg as auditor-in-charge;
to adopt principles for the appointment of a nomination committee (same principles as previous year); and
to authorize the board of directors to increase the share capital through issuance of new shares, warrants and/or convertible debentures. New issues of shares and issues of warrants and/or convertibles may occur with or without preferential rights for shareholders of the Company and may be made either in cash and/or by way of set-off or contribution in kind or otherwise be conditional. Through issuances resolved upon with support from the authorization – with deviation from the shareholders’ preferential rights – the number of shares issued, or number of shares created in connection with exercise of warrants or conversion of convertibles, shall correspond to not more than a 20 per cent dilution of the share capital and the number of shares and votes in the Company after such issue(s).

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com

Certified Advisor (CA):

Vator Securities

Tel: +46 8 580 065 99

Email: ca@vatorsec.se

The information was submitted, through the agency of the contact person set out above, for publication at the time stated by SciBase’s news distributor Cision upon publication of this press release.

About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase’s products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.

Downloads

2022-02-23 08:00

January 1 – December 31, 2021

The fourth quarter in figures

Net sales amounted to TSEK 3,925 (3,055).
The loss after tax amounted to TSEK 13,852 (9,839).
The loss per share amounted to SEK 0.20 (0.20).
The cash flow from current operations was negative in the amount of TSEK 11,709 (10,290).
The gross margin reached 52.8% (49.4%).
Electrode sales volume increased by 7% and reached 8,024 (7,492) units. Repeat sales of electrodes to existing customers increased by 12%.

The full year in figures

Net sales amounted to TSEK 11,727 (9,521).
The loss after tax amounted to TSEK 41,778 (34,989).
The loss per share amounted to SEK 0.67 (1.12).
The cash flow from current operations was negative in the amount of TSEK 39,501 (33,861).
The gross margin reached 56.1% (52.5%).
Electrode sales volume increased by 16% and reached 29,792 (25,686) units. Repeat sales of electrodes to existing customers increased by 12%.

Important events during the quarter

Overall sales increased by 28% (+34%, before currency effects). Covid-19 continues to affect sales and the market situation remains difficult to predict going forward, due to ongoing lockdowns and reduced marketing activities. The sales in the important US market increased within the area of skin cancer by 395% (in local currency by 415%). Sales in Germany decreased by 18% (-14% in local currency).
A request for a Medicare payment assignment for the Nevisense procedure was submitted to National Government Services (NGS), the Medicare Administrative Contractor with carrier jurisdiction responsibility for New York and several other states.
SciBase received an order of ten additional Nevisense systems and electrodes valued at approximately KUSD 100 from Advanced Dermatology, P.C. (AdvDermPC) in New York City.
A nominating committee for the AGM 2022 was appointed.

Important events after the end of the period

A new study from the US supporting the use of Nevisense in diagnosing melanoma was published in “SKIN – The journal of cutaneous medicine”. The study shows that Nevisense provides valuable diagnostic guidance when evaluating atypical pigmented skin lesions.
SciBase announced a change in the Management team and a new head of Quality and Regulatory Affairs.

Financial overview

	Oct 1 – Dec 31	Jan 1 – Dec 31
THE GROUP	2021	2020	2021	2020
Net sales, SEK ths	3 925	3 055	11 727	9 521
Gross margin, %	52,8%	49,4%	56,1%	52,5%
Equity/Asset ratio, %	82,8%	79,1%	82,8%	79,1%
Net indebtness, multiple	0,21	0,26	0,21	0,26
Cash equivalents, SEK ths	65 607	41 427	65 607	41 427
Cashflow from operating activities, SEK ths	-11 709	-10 290	-39 501	-33 861
Earnings per share (before and after dilution), SEK	-0,20	-0,20	-0,67	-1,12
Shareholder’s equity per share, SEK	1,03	0,96	1,16	1,50
Average number of shares, 000′	68 475	48 707	60 827	31 287
Number of shares at closing of period, 000′	68 475	54 780	68 475	54 780
Share price at end of period, SEK	5,52	4,62	5,52	4,62
Number of sold electrodes, pieces	8 024	7 492	29 792	25 686
Average number of employees	18	17	17	16

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on February 23, 2022.

Contact person: Michael Colérus, CFO. +46 70 341 34 72

For more information, please contact:
Simon Grant, CEO SciBase
Phone: +46 72 887 43 99
Email: simon.grant@scibase.com

Certified Advisor:
Vator Securities
Tel: +46 8 580 065 99
Email: ca@vatorsec.se

Downloads

Report (PDF